Treatment | All N = 414 | No irAE N = 316 | irAE N = 98 | p-value |
---|---|---|---|---|
Settings |  |  |  | < 0.001 |
 Clinical trial | 161 (38.9) | 102 (32.3) | 59 (60.2) |  |
 Compassionate program | 31 (7.5) | 26 (8.2) | 5 (5.1) |  |
 Clinical practice | 222 (53.6) | 188 (59.5) | 34 (34.7) |  |
Treatment setting | Â | Â | Â | 0.074 |
 Adjuvant | 6 (1.4) | 5 (1.6) | 1 (1.0) |  |
 1st line metastasis | 214 (51.7) | 152 (48.1) | 62 (63.3) |  |
 2nd line metastasis | 113 (27.3) | 92 (29.1) | 21 (21.4) |  |
  ≥ 3rd line metastasis | 81 (19.6) | 67 (21.2) | 14 (14.3) |  |
Immunotherapy combination | Â | Â | Â | 0.004 |
 Single agent | 322 (77.8) | 250 (79.1) | 72 (73.5) |  |
 Combination ICI + ICI | 19 (4.6) | 8 (2.5) | 11 (11.2) |  |
 Combination ICI + chemotherapy | 62 (15.0) | 50 (15.8) | 12 (12.2) |  |
 Combination ICI + others | 11 (2.7) | 8 (2.5) | 3 (3.1) |  |